AdobeStock_1186573671

EFSA Press Release

Bangalore, India | 30, Jan 2025

Bioplus Secures Regulatory Approval from EFSA for Algal DHA in Infant Formula

Bioplus Life Sciences, a pioneer in biotechnology and nutrition, has achieved a significant milestone by securing EFSA (European Food Safety Authority) approval for the use of its algal DHA oil and powder in infant formula.

Bioplus’ BioDHA Algal Oil is derived from a proprietary microalgae strain, Schizochytrium sp. ATCC 20889, cultivated in a controlled environment to ensure purity, quality, and freedom from ocean-borne contaminants commonly found in fish-derived DHA sources. This approval marks a major breakthrough in delivering a sustainable, plant-based source of essential omega-3 fatty acids for infant nutrition.

DHA (docosahexaenoic acid) is a critical omega-3 fatty acid that plays a vital role in brain development, cognitive function, and visual acuity in infants; especially crucial for expecting mothers to help the infant develop in the first two years of life.

“We are thrilled to introduce a sustainable and high-purity DHA solution for infant nutrition,” said “Sundeep Aurora, Chairman & Managing Director of Bioplus Life Sciences. “Our mission is to provide innovative, high-quality, and accessible nutritional solutions that support healthy development from the very start of life.”

Available:

Microencapsulated Powder Low Saturated Fat Oil

105-135 mg/g | 170-200 mg/g

Low Saturated Fat Oil

35%, 40%, 45%, 50%

Ultra Low Saturated Fat Oil

40%, 45%, 50%

Bioplus Life Sciences

Bioplus, developing lifesaving technologies of the future.

Bioplus Life Sciences is a leading biopharmaceutical company with over 75 years of experience serving the pharmaceutical industry. Building on a strong foundation of high-quality products, services, and technology in contract manufacturing and generic pharmaceuticals. Bioplus today is a late-stage clinical phase company focused on developing novel therapeutics to address significant global unmet needs.

The company has two clinical phase-3 ready programs targeting global blockbuster potential. As well as a robust pipeline of pre-clinical programs, positioning us for significant growth over the next five years as our groundbreaking novel therapeutics enter the market. Bioplus intends to partner with leading regional and global companies to optimize product market access. 

Notably, it is the only company in India to have successfully commercialized microalgal fermentation for Omega-3 fatty acids.

A pioneer in advanced fermentation biotechnology, Bioplus holds over 40 patents and possesses more than 15 years of expertise. Complementing this expertise, Bioplus operates a state-of-the-art synthetic biology lab dedicated to the development of innovative recombinant proteins, peptides, and pharmaceutical ingredients. With over 14 drug candidates in development and established partnerships with leading universities across India, the USA, and Europe, Bioplus remains committed to cutting-edge research and development.

The company is significantly investing in R&D, clinical development, and CAPEX for capacity and capability expansion, anticipating significant growth over the next 5 years as its novel therapeutics reach the market. Bioplus is driven by scientific curiosity, focused on targeted clinical development, and dedicated to contributing to the health and wellbeing of global citizens.

We stay rooted in our moto to continuously – Innovate, Explore, Develop..

For Enquires:

Marc Lesieur, VP – Business Development marc@bioplus.in

www.bioplus.in